| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Unit of Prevention and Genetic Epidemiology [V. B., C. L.] and Departments of Psycho-Oncology [P. S], Medical Oncology [F. D.], Surgical Oncology [H. M.], and Molecular Oncology [Q. W., A. P.], Comprehensive Cancer Center Léon Bérard; Department of Gastroenterology [J-C. S.] and Laboratory of Genetics [O. S., S. G.], Edouard Herriot Hospital, 69; International Agency for Research on Cancer [O. S.]; Department of Radiotherapy and Oncology, Lyon-Sud Hospital Center [G. F.]; and Department of Medical Genetics, Hôtel Dieu Hospital [H. P.], 69 008 Lyon, France
The aim of this prospective study was to evaluate the consequences of the disclosure of a positive genetic test result to patients affected with cancer. Personal repercussions and patients behavior with the transmission of their results to relatives were considered. We conducted semistructured interviews with 23 cancer patients identified as carriers of a cancer-predisposing mutation for hereditary breast ovarian or nonpolyposis colorectal cancers, 1 month after the disclosure of the test result. Eight patients spontaneously expressed distressed reactions ("you no longer feel cured"), and 14 patients reported at least one negative feeling (dissatisfied, discouraged, unhappy, or worried), despite expecting to be a carrier. Sixteen patients expressed concerns about the risk of developing another cancer, and 18 were concerned for their childrens future, in that they may carry the mutation and develop a cancer. Although 8 patients found that disadvantages of knowing their genetic status outweighed the advantages, all but 1 did not regret having undergone genetic testing. All of the patients transmitted their results to at least one close relative. Although 6 of them expressed difficulties in being the only person who could transmit the information and 9 said it was a heavy responsibility, all except 1 did not want someone else to have to inform their families. Our results illustrate the potential negative impact of diagnostic genetic testing in patients with cancer. This includes distressed reactions and difficulties in transmitting their results to relatives. Future large-scale studies are warranted to confirm our findings.
This article has been cited by other articles:
![]() |
A. R. Bradbury, J. J. Dignam, C. N. Ibe, S. L. Auh, F. J. Hlubocky, S. A. Cummings, M. White, O. I. Olopade, and C. K. Daugherty How Often Do BRCA Mutation Carriers Tell Their Young Children of the Family's Risk for Cancer? A Study of Parental Disclosure of BRCA Mutations to Minors and Young Adults J. Clin. Oncol., August 20, 2007; 25(24): 3705 - 3711. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Tamvakopoulos, K. Dimas, Z. D. Sofianos, S. Hatziantoniou, Z. Han, Z.-L. Liu, J. H. Wyche, and P. Pantazis Metabolism and Anticancer Activity of the Curcumin Analogue, Dimethoxycurcumin Clin. Cancer Res., February 15, 2007; 13(4): 1269 - 1277. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. F. Patenaude, M. Dorval, L. S. DiGianni, K. A. Schneider, A. Chittenden, and J. E. Garber Sharing BRCA1/2 Test Results With First-Degree Relatives: Factors Predicting Who Women Tell J. Clin. Oncol., February 1, 2006; 24(4): 700 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Garcea, D. P. Berry, D. J.L. Jones, R. Singh, A. R. Dennison, P. B. Farmer, R. A. Sharma, W. P. Steward, and A. J. Gescher Consumption of the Putative Chemopreventive Agent Curcumin by Cancer Patients: Assessment of Curcumin Levels in the Colorectum and their Pharmacodynamic Consequences Cancer Epidemiol. Biomarkers Prev., January 1, 2005; 14(1): 120 - 125. [Abstract] [Full Text] [PDF] |
||||
![]() |
R Timman, T Stijnen, and A Tibben Methodology in longitudinal studies on psychological effects of predictive DNA testing: a review J. Med. Genet., July 1, 2004; 41(7): e100 - e100. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. R. Smith, L. Ellington, A. Y. Chan, R. T. Croyle, and J. R. Botkin Fertility Intentions Following Testing for a BRCA1 Gene Mutation Cancer Epidemiol. Biomarkers Prev., May 1, 2004; 13(5): 733 - 740. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |